Brimonidine is an alpha-adrenergic agonist indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. It is available as eye drops, gel and ophthalmic solution for topical use. MedsAcross supplies Brimonidine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
ALPHAGAN P (brimonidine tartrate ophthalmic solution) 0.1% or 0.15% is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. ALPHAGAN P is an alpha adrenergic agonist indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Source: US FDA prescribing information
ALPHAGAN P is a relatively selective alpha-2 adrenergic receptor agonist with a peak ocular hypotensive effect occurring at two hours post-dosing. Fluorophotometric studies in animals and humans suggest that brimonidine tartrate has a dual mechanism of action by reducing aqueous humor production and increasing uveoscleral outflow.
Source: US FDA prescribing information
The recommended dosage is one drop of ALPHAGAN P in the affected eye(s) three times daily, approximately 8 hours apart. ALPHAGAN P may be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure. If more than one topical ophthalmic product is to be used, the different products should be instilled at least 5 minutes apart. One drop in the affected eye(s) three times daily, approximately 8 hours apart.
Source: US FDA prescribing information
Neonates and infants (pediatric patients younger than 2 years old). Hypersensitivity Reactions. Neonates and Infants (Pediatric Patients Younger than 2 Years Old) ALPHAGAN P is contraindicated in neonates and infants (pediatric patients younger than 2 years old).
Source: US FDA prescribing information
Potentiation of vascular insufficiency. Potentiation of Vascular Insufficiency ALPHAGAN P may potentiate syndromes associated with vascular insufficiency. ALPHAGAN P should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud’s phenomenon, orthostatic hypotension, or thromboangiitis obliterans.
Source: US FDA prescribing information
The following serious adverse reactions are described elsewhere in the labeling: Potentiation of Vascular Insufficiency Severe Cardiovascular Disease Contamination of Topical Ophthalmic Products after Use Neonates and Infants (Pediatric Patients Younger than 2 Years Old) Most common adverse reactions occurring in approximately 5% to 20% of patients receiving brimonidine ophthalmic solution (0.1% to 0.2%) included allergic conjunctivitis, burning sensation, conjunctival folliculosis, conjunctival hyperemia, eye pruritus, hypertension, ocular allergic reaction, oral dryness, and visual disturbance.
Source: US FDA prescribing information
Antihypertensives/cardiac glycosides may lower blood pressure. Use with CNS depressants may result in an additive or potentiating effect. Tricyclic antidepressants may potentially blunt the hypotensive effect of systemic clonidine. Monoamine oxidase inhibitors may result in increased hypotension.
Source: US FDA prescribing information
Store at 15 o C to 25 o C (59 o F to 77 o F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
10 presentations of Brimonidine, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Brimonidine 1 mg/mL eye dropsOphthalmicGeneric name | — | US FDA | Available on request |
| Brimonidine 1.5 mg/mL eye dropsOphthalmicGeneric name | — | US FDA | Available on request |
| Brimonidine 2 mg/mL eye dropsOphthalmicGeneric name | — | US FDA | Available on request |
| Brimonidine 2 mg/mg eye dropsOphthalmicGeneric name | — | US FDA | Available on request |
| Alphagan P 1 mg/mL eye dropsOphthalmic | Allergan | US FDA | Available on request |
| Alphagan P 1.5 mg/mL eye dropsOphthalmic | Allergan | US FDA | Available on request |
| Brimonidine 0.5% gelTopicalGeneric name | — | US FDA | Available on request |
| Brimonidine 1.5 mg/mL ophthalmic solutionOphthalmicGeneric name | — | US FDA | Available on request |
| Brimonidine 2 mg/mL ophthalmic solutionOphthalmicGeneric name | — | US FDA | Available on request |
| Mirvaso 0.5% gelTopical | Galderma Laboratories | US FDA | Available on request |
2 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Conditions linked to Brimonidine in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 10 presentations of Brimonidine and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 2 brand names for Brimonidine, including Alphagan P, Mirvaso.
Yes. The US FDA first approved Brimonidine on 6 September 1996, according to Drugs@FDA.
Yes. Brimonidine has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
No listed presentation of Brimonidine is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Brimonidine is classified under ATC code D11AX21 (Brimonidine).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.